Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markolf Hanefeld

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
Cardiovascular Diabetology|April 12, 2013
The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetesDiethelm Tschöpe, Markolf Hanefeld, Juris J Meier, et al.
Clinical Therapeutics|March 8, 2006
Postprandial glucose regulation: new data and new implicationsLawrence A Leiter, Antonio Ceriello, Jaime A Davidson, et al.
Journal of the American College of Cardiology|April 26, 2008
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled studyEmile R Mohler, Christie M Ballantyne, Michael H Davidson, et al.
Diabetes|September 28, 2002
In vivo evidence for increased oxidation of circulating LDL in impaired glucose toleranceSteffi Kopprasch, Jens Pietzsch, Eberhard Kuhlisch, et al.
Diabetes, Obesity & Metabolism|April 28, 2017
Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairmentMarkolf Hanefeld, Juan M Arteaga, Lawrence A Leiter, et al.
Metabolism: Clinical and Experimental|March 24, 2007
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT StudyThomas Forst, Andreas Pfützner, Georg Lübben, et al.
Diabetes Care|June 28, 2006
Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoterPeter E H Schwarz, Gordon W Towers, Sabine Fischer, et al.
Diabetes & Vascular Disease Research|October 30, 2008
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular riskThomas Forst, Birgit Wilhelm, Andreas Pfützner, et al.
Plos One|October 10, 2017
Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetesMarkolf Hanefeld, Katrin Engelmann, Dieter Appelt, et al.
The Journal of Clinical Endocrinology and Metabolism|September 10, 2004
Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosisTheodora Temelkova-Kurktschiev, Markolf Hanefeld, Giulia Chinetti, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
Cardiovascular Diabetology|April 12, 2013
The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetesDiethelm Tschöpe, Markolf Hanefeld, Juris J Meier, et al.
Clinical Therapeutics|March 8, 2006
Postprandial glucose regulation: new data and new implicationsLawrence A Leiter, Antonio Ceriello, Jaime A Davidson, et al.
Journal of the American College of Cardiology|April 26, 2008
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled studyEmile R Mohler, Christie M Ballantyne, Michael H Davidson, et al.
Diabetes|September 28, 2002
In vivo evidence for increased oxidation of circulating LDL in impaired glucose toleranceSteffi Kopprasch, Jens Pietzsch, Eberhard Kuhlisch, et al.
Diabetes, Obesity & Metabolism|April 28, 2017
Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairmentMarkolf Hanefeld, Juan M Arteaga, Lawrence A Leiter, et al.
Metabolism: Clinical and Experimental|March 24, 2007
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT StudyThomas Forst, Andreas Pfützner, Georg Lübben, et al.
Diabetes Care|June 28, 2006
Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoterPeter E H Schwarz, Gordon W Towers, Sabine Fischer, et al.
Diabetes & Vascular Disease Research|October 30, 2008
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular riskThomas Forst, Birgit Wilhelm, Andreas Pfützner, et al.
Plos One|October 10, 2017
Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetesMarkolf Hanefeld, Katrin Engelmann, Dieter Appelt, et al.
The Journal of Clinical Endocrinology and Metabolism|September 10, 2004
Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosisTheodora Temelkova-Kurktschiev, Markolf Hanefeld, Giulia Chinetti, et al.
Pageof 13